@article{lawitz:hal-01142117,
TITLE = {Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.},
AUTHOR = {Lawitz, Eric and Gane, Edward and Pearlman, Brian and Tam, Edward and Ghesquiere, Wayne and Guyader, Dominique and Alric, Laurent and Bronowicki, Jean-Pierre and Lester, Laura and Sievert, William and Ghalib, Reem and Balart, Luis and Sund, Fredrik and Lagging, Martin and Dutko, Frank and Shaughnessy, Melissa and Hwang, Peggy and Howe, Anita y M and Wahl, Janice and Robertson, Michael and Barr, Eliav and Haber, Barbara},
URL = {https://univ-rennes.hal.science/hal-01142117},
NOTE = {Comment in New kids on the block--step by step to an ideal HCV therapy. [Lancet. 2015]},
JOURNAL = {The Lancet},
PUBLISHER = {Elsevier},
VOLUME = {385},
NUMBER = {9973},
PAGES = {1075-86},
YEAR = {2015},
MONTH = Mar, DOI = {10.1016/S0140-6736(14)61795-5},
KEYWORDS = {Female ; Hepacivirus / genetics ; Hepatitis C Chronic / complications ; Hepatitis C Chronic / drug therapy ; Humans ; Imidazoles / administration \& dosage ; Interferons / therapeutic use ; Liver Cirrhosis / etiology ; Male ; Middle Aged ; Polyethylene Glycols / therapeutic use ; Quinoxalines / administration \& dosage ; RNA Viral / blood ; Ribavirin / administration \& dosage ; Sulfonamides ; Treatment Failure ; Treatment Outcome ; Viral Load ; Young Adult ; Adolescent ; Adult ; Aged ; Aged 80 and over ; Amides ; Antiviral Agents / administration \& dosage ; Benzofurans / administration \& dosage ; Carbamates ; Cyclopropanes ; Drug Administration Schedule ; Drug Therapy Combination},
HAL_ID = {hal-01142117},
HAL_VERSION = {v1},
}